Sultopride
Antipsychotic medication
- N05AL02 (WHO)
- N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
- 53583-79-2
N
- 5357
- 5164
Y
- AA0G3TW31W
- D08549 Y
- ChEMBL277945 Y
- DTXSID9023627
- Interactive image
- O=S(=O)(c1cc(c(OC)cc1)C(=O)NCC2N(CC)CCC2)CC
InChI
- InChI=1S/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)Y
- Key:UNRHXEPDKXPRTM-UHFFFAOYSA-NY
N
Y (what is this?) (verify)Sultopride (trade names Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[2][3][4] It was launched by Sanofi-Aventis in 1976.[2] Sultopride acts as a selective D2 and D3 receptor antagonist.[5] It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[6]
Pharmacology
| Site | Ki | Species | Ref |
|---|---|---|---|
| D2 | 1.6 | Human | [7] |
| D3 | 3.8 | Human | [7] |
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ a b Miguel Vela J, Buschmann H, Holenz J, Párraga A, Torrens A (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 978-3-527-31058-6.
- ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
- ^ European Drug Index (4th ed.). Boca Raton: CRC Press. 1998. ISBN 3-7692-2114-1.
- ^ Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, et al. (December 2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–1287. doi:10.1124/jpet.105.092155. PMID 16135699. S2CID 2247093.
- ^ Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (April 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". European Journal of Pharmacology. 256 (2): 211–214. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.
- ^ a b Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, et al. (December 2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–1287. doi:10.1124/jpet.105.092155. PMID 16135699. S2CID 2247093.
- v
- t
- e
- Butyrophenones: Benperidol
- Bromperidol
- Droperidol
- Haloperidol#
- Moperone
- Pipamperone
- Spiperone
- Timiperone
- Trifluperidol
- Phenothiazines: Acepromazine
- Acetophenazine
- Butaperazine
- Carphenazine (carfenazine)‡
- Chlorpromazine
- Cyamemazine
- Dixyrazine
- Fluphenazine
- Levomepromazine (methotrimeprazine)
- Mesoridazine
- Perazine
- Periciazine
- Perphenazine
- Piperacetazine
- Pipotiazine
- Prochlorperazine
- Promazine
- Sulforidazine
- Thiopropazate
- Thioproperazine
- Thioridazine
- Trifluoperazine
- Triflupromazine
- Others/unknown: Azacyclonol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
